OverviewSuggest Edit

Aprea Therapeutics is a pharmaceutical development company that is engaged in the discovery and development of anticancer compounds targeting tumour suppressor proteins. The company offers p53, a tumor suppressor protein that responds to various forms of cellular stresses and activates transcription of genes that induce cell cycle arrest or apoptosis; APR-246 that reactivates mutant and defective native p53, leading to tumor cell death; and APR-017, which induces p53-mediated apoptosis by restoring p53 activity in cancer cell lines with mutant p53.
TypePublic
Founded2003
HQSolna, SE
Websiteaprea.com

Latest Updates

Employees (est.) (Sept 2019)14
Share Price (Sept 2021)$4.4(-4%)
Cybersecurity ratingAMore

Key People/Management at Aprea Therapeutics

Scott M. Rocklage

Scott M. Rocklage

Chairman
Christian Schade

Christian Schade

Chairman, Chief Executive Officer
Lars Abrahmsen

Lars Abrahmsen

Senior Vice President and Chief Scientific Officer
Scott M. Coiante

Scott M. Coiante

Senior Vice President and Chief Financial Officer
Eyal Attar

Eyal Attar

Senior Vice President and Chief Medical Officer
Guido Magni

Guido Magni

Director
Show more

Aprea Therapeutics Office Locations

Aprea Therapeutics has offices in Solna and Boston
Solna, SE (HQ)
Olof af Acrels väg 4-6
Boston, MA, US
535 Boylston St
Show all (2)

Aprea Therapeutics Financials and Metrics

Aprea Therapeutics Revenue

USD

Net income (Q1, 2021)

(9.7m)

Market capitalization (8-Sept-2021)

94.1m

Closing stock price (8-Sept-2021)

4.4

Cash (31-Mar-2021)

77.6m

EV

16.7m
Aprea Therapeutics's current market capitalization is $94.1 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

General and administrative expense

2.5m2.3m8.6m14.9m

R&D expense

13.4m14.2m21.0m37.9m

Operating expense total

15.9m16.5m29.5m52.8m

Interest expense

15.0182.0156.4k222.7k
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

General and administrative expense

2.3m2.8m3.8m3.5m3.4m

R&D expense

4.9m9.1m10.7m8.8m6.8m

Operating expense total

7.2m11.9m14.5m12.2m10.2m

Interest expense

6.1k224.4k2.7k9.2k1.1k
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

65.7m130.1m89.0m

Prepaid Expenses

3.0m3.4m

Current Assets

66.0m133.0m92.4m

PP&E

24.5k41.6k38.5k
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

61.0m52.3m122.5m112.9m101.1m77.6m

Prepaid Expenses

624.6k339.8k2.1m1.5m1.3m2.5m

Current Assets

61.9m56.7m124.6m114.3m102.4m80.1m

PP&E

25.7k31.0k45.9k43.9k40.7k33.6k
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(15.2m)(15.5m)(28.1m)(53.5m)

Depreciation and Amortization

7.9k8.3k11.1k28.8k

Accounts Payable

327.1k214.4k437.5k2.3m

Cash From Operating Activities

(14.0m)(15.3m)(26.7m)(41.8m)
Quarterly
USDQ2, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(7.7m)(8.7m)(15.0m)(9.4m)(25.8m)(38.1m)(9.7m)

Depreciation and Amortization

4.3k4.7k8.9k3.8k7.9k12.2k3.6k

Accounts Payable

(51.4k)640.7k2.0m829.8k3.3m2.2m(1.0m)

Cash From Operating Activities

(8.2m)(9.8m)(16.2m)(7.5m)(17.2m)(28.6m)(11.5m)
Show all financial metrics

Aprea Therapeutics Operating Metrics

Sep, 2019

Phase II Trials Products (Frontline)

2

Phase III Trials Products (Frontline)

1

Pre-Clinical Phase Products

1

Preclinical Phase Products (Frontline and Relapsed / Refractory)

1
Show all operating metrics

Aprea Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Aprea Therapeutics AB
Aprea US

Aprea Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Aprea Therapeutics Online and Social Media Presence

Embed Graph

Aprea Therapeutics News and Updates

Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations

BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three and six months…

Karolinska Development's portfolio company Aprea Therapeutics announces that FDA has issued a clinical hold on lymphoid malignancy program

STOCKHOLM, SWEDEN – August 12, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the US Food and Drug Administration (FDA) has issued a clinical hold for Aprea Therapeutics clinical program evaluating eprenetapopt with acalabrutinib or venetoclax and rituximab in lymphoid…

Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program

BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) …

Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) …

Karolinska Development’s portfolio company Aprea Therapeutics announces positive Phase 2 results for eprenetapopt

STOCKHOLM SWEDEN – July 22, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company Aprea Therapeutics has reported positive results from a Phase 2 trial evaluating its drug candidate eprenetapopt with azacitidine for post-transplant maintenance therapy in…

Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML

BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced positive results from its Phase 2 trial evaluatin…
Show more

Aprea Therapeutics Blogs

Aprea Therapeutics Appoints Scott Coiante as Chief Financial Officer

Aprea Therapeutics Appoints Scott Coiante as Chief Financial Officer

Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)

Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)

Results From Combination of APR-246 with Immuno-Oncology Agents Presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta

Results From Combination of APR-246 with Immuno-Oncology Agents Presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta

Aprea Therapeutics Appoints Dr. Eyal C. Attar as Chief Medical Officer

Aprea Therapeutics Appoints Dr. Eyal C. Attar as Chief Medical Officer

Aprea Therapeutics Closes EUR 50 Million Financing

Aprea Therapeutics Closes EUR 50 Million Financing

Aprea Therapeutics Frequently Asked Questions

  • When was Aprea Therapeutics founded?

    Aprea Therapeutics was founded in 2003.

  • Who are Aprea Therapeutics key executives?

    Aprea Therapeutics's key executives are Scott M. Rocklage, Christian Schade and Lars Abrahmsen.

  • How many employees does Aprea Therapeutics have?

    Aprea Therapeutics has 14 employees.

  • Who are Aprea Therapeutics competitors?

    Competitors of Aprea Therapeutics include Alembic Pharmaceuticals, EMS Pharma and Livzon Pharmaceutical Group.

  • Where is Aprea Therapeutics headquarters?

    Aprea Therapeutics headquarters is located at Olof af Acrels väg 4-6, Solna.

  • Where are Aprea Therapeutics offices?

    Aprea Therapeutics has offices in Solna and Boston.

  • How many offices does Aprea Therapeutics have?

    Aprea Therapeutics has 2 offices.